These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

941 related items for PubMed ID: 19919376

  • 1. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.
    Tunis SL, Minshall ME.
    Curr Med Res Opin; 2010 Jan; 26(1):151-62. PubMed ID: 19919376
    [Abstract] [Full Text] [Related]

  • 2. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
    Tunis SL, Willis WD, Foos V.
    Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
    [Abstract] [Full Text] [Related]

  • 3. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
    Tunis SL.
    Appl Health Econ Health Policy; 2011 Nov 01; 9(6):351-65. PubMed ID: 21892840
    [Abstract] [Full Text] [Related]

  • 4. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M, Minshall ME, Pandya BJ, Baran RW, Tunis SL.
    Curr Med Res Opin; 2009 Jun 01; 25(6):1343-53. PubMed ID: 19419339
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ.
    Adv Ther; 2008 Aug 01; 25(8):752-74. PubMed ID: 18704282
    [Abstract] [Full Text] [Related]

  • 6. Is the frequency of self-monitoring of blood glucose related to long-term metabolic control? Multicenter analysis including 24,500 patients from 191 centers in Germany and Austria.
    Schütt M, Kern W, Krause U, Busch P, Dapp A, Grziwotz R, Mayer I, Rosenbauer J, Wagner C, Zimmermann A, Kerner W, Holl RW, DPV Initiative.
    Exp Clin Endocrinol Diabetes; 2006 Jul 01; 114(7):384-8. PubMed ID: 16915542
    [Abstract] [Full Text] [Related]

  • 7. Impact of self-measurement of blood glucose on complications of type 2 diabetes: economic analysis from a Czech perspective.
    Weber C, Kocher S, Neeser K, Bartaskova D.
    Curr Med Res Opin; 2010 Feb 01; 26(2):289-96. PubMed ID: 19947908
    [Abstract] [Full Text] [Related]

  • 8. Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the united states.
    Tunis SL, Minshall ME.
    Am J Manag Care; 2008 Mar 01; 14(3):131-40. PubMed ID: 18333705
    [Abstract] [Full Text] [Related]

  • 9. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ, Palmer AJ, Lammert M, Langer J, Brändle M.
    Clin Ther; 2011 Nov 01; 33(11):1698-712. PubMed ID: 22018679
    [Abstract] [Full Text] [Related]

  • 10. Evaluating the cost-effectiveness of self-monitoring of blood glucose in type 2 diabetes patients on oral anti-diabetic agents.
    Pollock RF, Valentine WJ, Goodall G, Brändle M.
    Swiss Med Wkly; 2010 Nov 01; 140():w13103. PubMed ID: 21110238
    [Abstract] [Full Text] [Related]

  • 11. Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study.
    Davis WA, Bruce DG, Davis TM.
    Diabetes Care; 2006 Aug 01; 29(8):1764-70. PubMed ID: 16873777
    [Abstract] [Full Text] [Related]

  • 12. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting.
    Roze S, Valentine WJ, Evers T, Palmer AJ.
    Curr Med Res Opin; 2006 Jul 01; 22(7):1415-24. PubMed ID: 16834840
    [Abstract] [Full Text] [Related]

  • 13. Self-monitoring of blood glucose in people with type 1 and type 2 diabetes living in France: the Entred study 2001.
    Lecomte P, Romon I, Fosse S, Simon D, Fagot-Campagna A.
    Diabetes Metab; 2008 Jun 01; 34(3):219-26. PubMed ID: 18343703
    [Abstract] [Full Text] [Related]

  • 14. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
    Guillermin AL, Lloyd A, Best JH, DeYoung MB, Samyshkin Y, Gaebler JA.
    J Med Econ; 2012 Jun 01; 15(4):654-63. PubMed ID: 22369345
    [Abstract] [Full Text] [Related]

  • 15. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
    Lee WC, Samyshkin Y, Langer J, Palmer JL.
    J Med Econ; 2012 Jun 01; 15 Suppl 2():28-37. PubMed ID: 22834986
    [Abstract] [Full Text] [Related]

  • 16. Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: A microsimulation model and cost-effectiveness analysis from a US perspective with relevance to Medicaid.
    Frank J, Son D, Szafranski K, Poon Y.
    J Manag Care Spec Pharm; 2024 Sep 01; 30(9):917-928. PubMed ID: 39109990
    [Abstract] [Full Text] [Related]

  • 17. A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States.
    Pollock RF, Curtis BH, Valentine WJ.
    J Med Econ; 2012 Sep 01; 15(4):766-75. PubMed ID: 22413830
    [Abstract] [Full Text] [Related]

  • 18. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L, Zhao FL, Li SC.
    Int J Technol Assess Health Care; 2012 Oct 01; 28(4):436-44. PubMed ID: 23006540
    [Abstract] [Full Text] [Related]

  • 19. The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m(2) in Spain.
    Fonseca T, Clegg J, Caputo G, Norrbacka K, Dilla T, Alvarez M.
    J Med Econ; 2013 Jul 01; 16(7):926-38. PubMed ID: 23659201
    [Abstract] [Full Text] [Related]

  • 20. Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes.
    Palmer AJ, Dinneen S, Gavin JR, Gray A, Herman WH, Karter AJ.
    Curr Med Res Opin; 2006 May 01; 22(5):861-72. PubMed ID: 16709308
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.